1. Home
  2. TGE vs ACRV Comparison

TGE vs ACRV Comparison

Compare TGE & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGE

The Generation Essentials Group Class A Ordinary Shares

N/A

Current Price

$1.28

Market Cap

66.4M

ML Signal

N/A

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.67

Market Cap

56.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGE
ACRV
Founded
2023
2018
Country
France
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.4M
56.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
TGE
ACRV
Price
$1.28
$1.67
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$13.00
AVG Volume (30 Days)
67.4K
1.3M
Earning Date
10-20-2025
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.48
N/A
Revenue
$130,212,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$805.34
P/E Ratio
$2.67
N/A
Revenue Growth
316.50
N/A
52 Week Low
$0.78
$1.05
52 Week High
$37.02
$7.24

Technical Indicators

Market Signals
Indicator
TGE
ACRV
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
TGE
ACRV

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: